FIM
RGN

Frontier Investment Management’s REGENERX BIOPHARMACEUTICALS RGN Stock Holding History

Frontier Investment Management’s Portfolio RGN Stock Details RGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-100,040
Closed -$16K – 286
2018
Q4 		$16K Buy
+100,040
New +$16K ﹤0.01% 244

Other funds holding RGN

PTC
Philadelphia Trust Company Philadelphia, Pennsylvania $1.42B AUM 43.77% 1-Year Est. Return
WJA
Williams Jones & Associates New York $4.82B AUM 19.95% 1-Year Est. Return
DBIA
Dumont & Blake Investment Advisors Princeton, New Jersey $400M AUM 21.87% 1-Year Est. Return
CG
Colony Group Boston, Massachusetts $6.66B AUM 18.65% 1-Year Est. Return

Frontier Investment Management's RGN Position: Q1 2019 in Review

Frontier Investment Management sold out of REGENERX BIOPHARMACEUTICALS (RGN) in Q1 2019, closing a stake of 100,040 shares — an estimated $16K sold.

Frontier Investment Management first reported a position in RGN in Q4 2018 and held it in 1 quarter. The position peaked at $16K in Q4 2018. 4 funds tracked by Wall St. Rank hold RGN as of Q1 2019.

  • Frontier Investment Management reported no remaining REGENERX BIOPHARMACEUTICALS position as of Q1 2019 after selling out during the quarter.
  • Frontier Investment Management sold 100,040 REGENERX BIOPHARMACEUTICALS shares in Q1 2019, an estimated $16K.
  • Frontier Investment Management first reported a position in REGENERX BIOPHARMACEUTICALS in Q4 2018 and held it in 1 quarter.
  • Frontier Investment Management's REGENERX BIOPHARMACEUTICALS position peaked at $16K in Q4 2018.
  • 4 funds tracked by Wall St. Rank held REGENERX BIOPHARMACEUTICALS as of Q1 2019.

Based on Frontier Investment Management's 13F filing for Q1 2019, filed 14 May 2019.